The recent development of specific and sensitive serologic test for SV40, that has allowed the detection of specific serum antibodies against SV40 VPs [1] and the possibility to evaluate the levels of soluble HLA-G expression in biological fluids [8], suggested the analysis of these two components in sera from MS patients. This evidence concerns the gene HLA-G and myeloid sarcoma.